Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Nuvaxovid XBB.1.5

- PMLiVE

MHRA approves Bavarian Nordic’s chikungunya vaccine Vimkunya

Approximately 620,000 cases of the mosquito-borne viral disease were reported worldwide in 2024

- PMLiVE

Sanofi receives FDA fast track designation for COVID-19/flu combination vaccines

The combined vaccine approach could simplify immunisation practices and lead to higher uptake

- PMLiVE

MHRA urges companies to prepare for Windsor Framework for medicines

The new UK-wide arrangements for medicines will come into effect on 1 January 2025

- PMLiVE

Novavax announces FDA clinical hold lift on phase 3 COVID-19/flu vaccine study

The serious adverse event reported was found to be unrelated to the vaccine

- PMLiVE

Ipsen’s Iqirvo approved by MHRA to treat primary biliary cholangitis in adults

Approximately 25,000 people in the UK are affected by the rare liver disease

- PMLiVE

Moderna’s JN.1-adapted COVID-19 vaccine approved by MHRA for adults and children

The JCVI has already advised the UK government on eligible groups for this year’s autumn vaccination programme

- PMLiVE

Novavax’s JN.1-adapted COVID-19 vaccine granted FDA emergency use authorisation

JN.1 only accounts for 0.2% of cases across the country but is the ‘parent strain’ of currently circulating variants

- PMLiVE

FDA approves updated COVID-19 vaccines to better protect against current variants

Adapted vaccines from Pfizer/BioNTech and Moderna have been authorised for individuals aged six months and older

- PMLiVE

JCVI announces advice for autumn COVID-19 vaccination programme eligibility

The Committee has advised offering the vaccine to those at high risk of serious disease

- PMLiVE

Pfizer/BioNTech’s Omicron JN.1-adapted COVID-19 vaccine approved by MHRA

The UK regulator has approved four versions of the updated vaccine for adults and children from infancy

- PMLiVE

Novo Nordisk’s semaglutide approved by MHRA to prevent cardiovascular event risk

Approximately 7.6 million people are living with heart and circulatory diseases in the UK

- PMLiVE

MHRA approves first generic raltegravir medicines to treat HIV in adults and children

More than 91,000 people in England were diagnosed with HIV and accessing care in 2022

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links